Amicus Therapeutics

Jill Weimer, Ph.D., Chief Science Officer

Philadelphia, PA

(NASDAQ: FOLD)

Virtual Presentation

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases, including an industry leading rare disease gene therapy portfolio.

www.amicusrx.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions